Ataluren-Induced Functional Restoration of Neurofibromin in Fibroblasts From Neurofibromatosis Type 1 Patients With Nonsense Mutations

Abstract

Neurofibromatosis Type 1 (NF1) is an autosomal dominant genetic disorder caused by heterogeneous mutations in the tumor suppressor gene NF1. Neurofibromin, encoded by NF1, predominantly acts as a negative regulator of the RAS-MEK signaling pathway. Up to 30% of NF1 patients harbor nonsense mutations (NS) that introduce premature termination codons (PTCs). Ataluren is a well-characterized small molecule that acts as a nonsense suppressor by enhancing the ribosomal readthrough of PTCs. Here, we isolated primary fibroblasts from 22 Korean NF1^NS/+ patients and comprehensively evaluated the efficacy of ataluren treatment. The results demonstrate that hyperactivated GTP-bound RAS was significantly alleviated in approximately 23% of NF1^NS/+ fibroblasts, and the cellular levels of phosphorylated ERK also decreased in approximately 24% after ataluren treatment. Through transcriptome-wide profiling based on ataluren responsiveness, we analyzed a subset of genes in ataluren-treated NF1^NS/+ fibroblasts whose expression was significantly altered in ataluren-responsive cells, but not in nonresponsive cells. Furthermore, both AMPD3 and TGFBR3 were notably identified as feasible biomarkers for monitoring functional neurofibromin. Interestingly, AMPD3 can be an effective therapeutic target for NF1-associated diseases. Together, our study suggests that ataluren can be considered a therapeutic agent for some NF1^NS/+ patients and contributes to expanding insights into NF1 therapy.

Keywords

AMPD3 / ataluren / neurofibromatosis type 1 (NF1) / nonsense mutations / restored neurofibromin / TGFBR3

References

[1] J. M. Friedman, “Epidemiology of Neurofibromatosis Type 1,” American Journal of Medical Genetics 89, no. 1 (1999): 1–6.

[2] K. Cichowski and T. Jacks, “NF1 Tumor Suppressor Gene Function: Narrowing the GAP,” Cell 104, no. 4 (2001): 593–604.

[3] D. H. Gutmann, R. E. Ferner, R. H. Listernick, B. R. Korf, P. L. Wolters, and K. J. Johnson, “Neurofibromatosis Type 1,” Nature Reviews Disease Primers 3 (2017): 17004.

[4] J. Mo, S. L. Moye, R. M. McKay, and L. Q. Le, “Neurofibromin and Suppression of Tumorigenesis: Beyond the GAP,” Oncogene 41, no. 9 (2022): 1235–1251.

[5] E. Dombi, A. Baldwin, L. J. Marcus, et al., “Activity of Selumetinib in Neurofibromatosis Type 1-related Plexiform Neurofibromas,” New England Journal of Medicine 375, no. 26 (2016): 2550–2560.

[6] A. M. Gross, P. L. Wolters, E. Dombi, et al., “Selumetinib in Children With Inoperable Plexiform Neurofibromas,” New England Journal of Medicine 382, no. 15 (2020): 1430–1442.

[7] H. Kim, H. M. Yoon, E. K. Kim, et al., “Safety and Efficacy of Selumetinib in Pediatric and Adult Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma,” Neuro-oncology 26, no. 12 (2024): 2352–2363.

[8] M. Mort, D. Ivanov, D. N. Cooper, and N. A. Chuzhanova, “A Meta-Analysis of Nonsense Mutations Causing Human Genetic Disease,” Human Mutation 29, no. 8 (2008): 1037–1047.

[9] E. Kang, Y. M. Kim, G. H. Seo, et al., “Phenotype Categorization of Neurofibromatosis Type I and Correlation to NF1 Mutation Types,” Journal of Human Genetics 65, no. 2 (2020): 79–89.

[10] S. H. Osum, E. I. Oribamise, S. Corbiere, et al., “Combining Nonsense Mutation Suppression Therapy With Nonsense-Mediated Decay Inhibition in Neurofibromatosis Type 1,” Molecular Therapy Nucleic Acids 33 (2023): 227–239.

[11] E. M. Welch, E. R. Barton, J. Zhuo, et al., “PTC124 targets Genetic Disorders Caused by Nonsense Mutations,” Nature 447, no. 7140 (2007): 7187–7191.

[12] N. J. Ryan, “Ataluren: First Global Approval,” Drugs 74, no. 14 (2014): 1709–1714.

[13] C. Wu, S. Iyer, S. A. Wolfe, and A. Jacobson, “Functional Restoration of Mouse Nf1 Nonsense Alleles in Differentiated Cultured Neurons,” Journal of Human Genetics 67, no. 11 (2022): 661–668.

[14] C. Wu, M. S. Shazeeb, K. Mangkalaphiban, et al., “Investigating Therapeutic Nonsense Suppression in a Neurofibromatosis Mouse Model,” Experimental Neurology 380 (2024): 114914.

[15] T. Kurosaki, M. W. Popp, and L. E. Maquat, “Quality and Quantity Control of Gene Expression by Nonsense-Mediated mRNA Decay,” Nature Reviews Molecular Cell Biology 20, no. 7 (2019): 406–420.

[16] H. Li, L. J. Chang, D. R. Neubauer, D. F. Muir, and M. R. Wallace, “Immortalization of human Normal and NF1 Neurofibroma Schwann Cells,” Laboratory Investigation 96, no. 10 (2016): 1105–1115.

[17] C. Anastasaki, A. S. Woo, L. M. Messiaen, and D. H. Gutmann, “Elucidating the Impact of Neurofibromatosis-1 Germline Mutations on Neurofibromin Function and Dopamine-Based Learning,” Human Molecular Genetics 24, no. 12 (2015): 3518–3528.

[18] A. Leier, D. M. Bedwell, A. T. Chen, et al., “Mutation-Directed Therapeutics for Neurofibromatosis Type I,” Molecular Therapy Nucleic Acids 20 (2020): 739–753.

[19] S. Hirawat, E. M. Welch, G. L. Elfring, et al., “Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers,” Journal of Clinical Pharmacology 47, no. 4 (2007): 430–444.

[20] L. Linde, S. Boelz, M. Nissim-Rafinia, et al., “Nonsense-Mediated mRNA Decay Affects Nonsense Transcript Levels and Governs Response of Cystic Fibrosis Patients to Gentamicin,” Journal of Clinical Investigation 117, no. 3 (2007): 683–692.

[21] K. M. Keeling, D. Wang, Y. Dai, et al., “Attenuation of Nonsense-Mediated mRNA Decay Enhances in Vivo Nonsense Suppression,” PLoS ONE 8, no. 4 (2013): e60478.

[22] Z. Yi, M. Sanjeev, and G. Singh, “The Branched Nature of the Nonsense-Mediated mRNA Decay Pathway,” Trends in Genetics 37, no. 2 (2021): 143–159.

[23] S. Huang, A. Bhattacharya, M. D. Ghelfi, et al., “Ataluren Binds to Multiple Protein Synthesis Apparatus Sites and Competitively Inhibits Release Factor-Dependent Termination,” Nature Communications 13, no. 1 (2022): 2413.

[24] J. Baez-Flores, M. Rodriguez-Martin, and J. Lacal, “The Therapeutic Potential of Neurofibromin Signaling Pathways and Binding Partners,” Communications Biology 6, no. 1 (2023): 436.

[25] A. Luscan, G. Shackleford, J. Masliah-Planchon, et al., “The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis,” Clinical Cancer Research 20, no. 2 (2014): 358–371.

[26] X. Ye and T. J. Carew, “Small G Protein Signaling in Neuronal Plasticity and Memory Formation: The Specific Role of Ras Family Proteins,” Neuron 68, no. 3 (2010): 340–361.

[27] F. Perrone, L. Da Riva, M. Orsenigo, et al., “PDGFRA, PDGFRB, EGFR, and Downstream Signaling Activation in Malignant Peripheral Nerve Sheath Tumor,” Neuro-oncology 11, no. 6 (2009): 725–736.

[28] D. H. Ki, S. He, S. Rodig, and A. T. Look, “Overexpression of PDGFRA Cooperates With Loss of NF1 and p53 to Accelerate the Molecular Pathogenesis of Malignant Peripheral Nerve Sheath Tumors,” Oncogene 36, no. 8 (2017): 1058–1068.

[29] K. Strimbu and J. A. Tavel, “What Are Biomarkers?,” Current Opinion in HIV and AIDS 5, no. 6 (2010): 463–466.

[30] N. Ogasawara, H. Goto, Y. Yamada, T. Watanabe, and T. Asano, “AMP Deaminase Isozymes in Human Tissues,” Biochimica Et Biophysica Acta 714, no. 2 (1982): 298–306.

[31] M. Garcia-Gil, M. Camici, S. Allegrini, R. Pesi, and M. G. Tozzi, “Metabolic Aspects of Adenosine Functions in the Brain,” Frontiers in Pharmacology 12 (2021): 672182.

[32] C. M. Hsu, S. F. Chang, Y. T. Tsai, et al., “Down-Regulation of AMPD3 Is Associated With Poor Survival in Head and Neck Squamous Cell Carcinoma,” In Vivo (Athens, Greece) 36, no. 2 (2022): 704–712.

[33] F. Wang, Y. Liu, J. Jiang, et al., “High Expression of AMPD2 and Obesity Are Associated With Poor Prognosis in Colorectal Cancer,” International Journal of Clinical and Experimental Pathology 11, no. 1 (2018): 216–223.

[34] J. B. Pawlak and G. C. Blobe, “TGF-Beta Superfamily Co-Receptors in Cancer,” Developmental Dynamics 251, no. 1 (2022): 137–163.

[35] N. Akizu, V. Cantagrel, J. Schroth, et al., “AMPD2 regulates GTP Synthesis and Is Mutated in a Potentially Treatable Neurodegenerative Brainstem Disorder,” Cell 154, no. 3 (2013): 505–517.

[36] M. Wong, K. Funasaka, T. Obayashi, et al., “AMPD3 is Associated With the Malignant Characteristics of Gastrointestinal Stromal Tumors,” Oncology letters 13, no. 3 (2017): 1281–1287.

[37] G. H. Park, S. J. Lee, C. G. Lee, J. Kim, E. Park, and J. SY, “Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation Through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor,” International Journal of Molecular Sciences 22, no. 24 (2021): 13308.

[38] L. Dreesmann, U. Mittnacht, M. Lietz, and B. Schlosshauer, “Nerve Fibroblast Impact on Schwann Cell Behavior,” European Journal of Cell Biology 88, no. 5 (2009): 285–300.

[39] G. Jang, H. R. Shin, H. S. Do, et al., “Therapeutic Gene Correction for Lesch-Nyhan Syndrome Using CRISPR-Mediated Base and Prime Editing,” Molecular Therapy Nucleic Acids 31 (2023): 586–595.

[40] J. Wu, E. Dombi, E. Jousma, et al., “Preclincial Testing of Sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre Mouse Model of Plexiform Neurofibroma Using Magnetic Resonance Imaging,” Pediatric Blood & Cancer 58, no. 2 (2012): 173–180.

[41] C. A. Schneider, W. S. Rasband, and K. W. Eliceiri, “NIH Image to ImageJ: 25 Years of Image Analysis,” Nature Methods 9, no. 7 (2012): 671–675.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.